RDZNHIGH SIGNALFINANCIAL10-K

RDZN experienced a dramatic deterioration in cash position and asset base while meaningfully reducing operating losses.

The company's cash reserves fell by more than half to just $4.8M, creating potential liquidity concerns for this loss-making insurtech firm. While the reduced operating losses suggest some progress toward profitability, the severe cash burn and asset contraction indicate RDZN may need additional financing soon.

Comparing 2025-06-26 vs 2024-07-01View on EDGAR →
FINANCIAL ANALYSIS

RDZN's balance sheet contracted significantly, with total assets declining 44% and cash reserves dropping to $4.8M from $11.2M. The company showed operational improvement with operating losses narrowing meaningfully and net losses reduced by roughly 27%. However, operating cash flow worsened to -$18.1M, creating a concerning divergence between reported losses and actual cash consumption that suggests potential working capital or timing issues.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-56.8%
$11.2M$4.8M

Cash declined 56.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-45.9%
$49.8M$27.0M

Current assets declined 45.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-44%
$58.1M$32.6M

Total assets contracted 44% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
-28.1%
$3.7M$2.6M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
+26.9%
-$99.7M-$72.9M

Net income grew 26.9% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
-24%
$5.0M$3.8M

R&D spending cut 24% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+21.7%
-$77.7M-$60.8M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Operating Cash Flow
Cash Flow
-17.6%
-$15.4M-$18.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Liabilities
Balance Sheet
-15.1%
$68.6M$58.3M

Liabilities reduced 15.1% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-13.3%
$65.7M$56.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2025-06-26
PRIOR — 2024-07-01
ADDED
The number of Registrant s ordinary shares outstanding as of June 20, 2025 was 74,290,986 .
Form 10-K Summary 88 Signatures 89 i BASIS OF PRESENTATION Roadzen Inc.
Financial Conduct Authority ( FCA ) regulations and guidelines may continue to have an adverse impact on our business and operations in the U.K.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
is a leading Insurtech company on a mission to transform global auto insurance powered by advanced artificial intelligence ( AI ).
+7 more — sign up free →
REMOVED
The number of Registrant s ordinary shares outstanding as of June 26, 2024 was 68,440,829 .
Form 10-K Summary 89 Signatures F- 40 i BASIS OF PRESENTATION Roadzen Inc.
Financial Conduct Authority ("FCA") regulations and guidelines may have an adverse impact on our business and operations in the U.K.
is a leading Insurtech company on a mission to transform global auto insurance powered by advanced artificial intelligence ("AI").
Our operations are global, and our partners consist of market-leading insurance companies, fleets and automotive original equipment manufacturers ("OEMs") and carmakers, including AXA, SCOR, Arch, Soci t G n rale, Jaguar Land Rover, Audi, Mercedes, Volvo and several others.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →